Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innate Pharma S.A. ADR (NQ: IPHA )

2.530 +0.020 (+0.80%)
Streaming Delayed Price Updated: 1:54 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Innate Pharma S.A. ADR

< Previous 1 2 3 4 Next >
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
From Innate Pharma SA
Via Business Wire
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
From Innate Pharma SA
Via Business Wire
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports Third Quarter Financial Results
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Innate Pharma 2023 Financial Calendar
From Innate Pharma SA
Via Business Wire
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports First Half 2022 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
From Innate Pharma S.A.
Via Business Wire
Outcome of Innate Pharma’s 2022 Annual General Meeting
From Innate Pharma S.A.
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Innate Pharma Reports First Quarter 2022 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
From Innate Pharma SA
Via Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.